Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291603 | 0.86 | ALDH1A1 (0.44) | ALDH1A1NQO1SOS2CYP1A2CYP2C9 | |
| SCHEMBL7846050 | 0.73 | SOS2 (0.38) | ALDH1A1NQO1SOS2KDM4EEGLN2 | |
| SCHEMBL11916709 | 0.69 | SOS2 (0.36) | ALDH1A1NQO1SOS2L3MBTL1KDM4E | |
| SCHEMBL25268051 | 0.69 | KHK (0.36) | ALDH1A1NQO1SOS2NPSR1KDM4E | |
| SCHEMBL16372364 | 0.69 | SOS2 (0.48) | ALDH1A1NQO1SOS2CYP1A2CYP2C9 | |
| SCHEMBL31236710 | 0.69 | ERBB2 (0.41) | ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL22135837 | 0.69 | CAMKK2 (0.35) | ALDH1A1NQO1SOS2KDM4EEGLN2 | |
| SCHEMBL12377890 | 0.69 | ALDH1A1 (0.35) | ALDH1A1NQO1SOS2L3MBTL1KDM4E | |
| SCHEMBL701812 | 0.69 | NOS3 (0.44) | ALDH1A1NQO1SOS2KDM4EEGLN2 | |
| Hydrochloric Acid SCHEMBL16741017 | 0.68 | SOS2 (0.47) | NQO1SOS2CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092033-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Avistone Biotechnology Co., Ltd. (CN) | 2025-03-20 | — | — | US | disclosed |
| EP-4458818-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Avistone Biotechnology Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092033-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | CYP19A1, WEE1, WEE2 | ALDH1A1 876/4885NQO1 17/4885SOS2 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.